The drugmaker entered into an asset purchase agreement with an affiliate of New Mountain Capital, an investment firm. Under the agreement, Aceto will sell its chemicals business for $338 million in cash, plus assumption of liabilities.
In addition, Aceto intends to enter into a stalking-horse agreement for its subsidiary, Rising Pharmaceuticals.
Aceto will continue operations as it works to sell its assets.
More articles on pharmacy:
23andMe wants to become a drug company, has 13 drugs in its pipeline: 5 notes
J&J CEO on partnership with Apple: ‘We’re going to save lives’
Medicare would pay for CAR-T therapy under new proposal
